Role of endothelin ETA receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats
Open Access
- 24 December 2023
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 228, 116007
Abstract
No abstract availableKeywords
Funding Information
- H2020 Marie Skłodowska-Curie Actions
- Medical Research Council (MR/N020081/1)
- European Union (GA858070)
This publication has 52 references indexed in Scilit:
- Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsProceedings of the National Academy of Sciences, 2012
- Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic TherapiesGenes & Cancer, 2011
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 LevelsHypertension, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Angiogenesis, 2009
- The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?British Journal of Pharmacology, 2008
- Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibitionCellular Signalling, 2007
- The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairmentBritish Journal of Clinical Pharmacology, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor AntagonistClinical Pharmacokinetics, 2004